(Q30820719)

26 June 2017

1 reference

title

Intravenous immunoglobulin for treating sepsis and septic shock (English)

1 reference

26 June 2017

0 references

1 reference

M M Alejandria

1

1 reference

26 June 2017

M A Lansang

series ordinal

2

1 reference

26 June 2017

L F Dans

series ordinal

3

1 reference

26 June 2017

J B Mantaring

series ordinal

4

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Cochrane Database of Systematic Reviews

26 June 2017

2001

0 references

2000

0 references

published in

1 reference

26 June 2017

issue

1

1 reference

26 June 2017

2

0 references

page(s)

CD001090

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Treatment of septic thrombocytopenia with immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Pepsin-Treated Human Gamma Globulin in Bacterial Infections: A Randomized Study in Patients with Septicaemia and Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous immune globulin therapy for early-onset sepsis in premature neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Safety of intravenous immunoglobulin infusion in neonates at risk for sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Antibody to lipoid A in the treatment of septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Administration of intravenous immunoglobulins for prophylaxis or treatment of infection in preterm infants: meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Impact of immunomodulating therapy on morbidity in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Sepsis therapy trials. Continued disappointment or reason for hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Improving clinical trials in the critically ill: unique challenge--sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

A critical evaluation of new agents for the treatment of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Large trials vs meta-analysis of smaller trials: how do their results compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous Immunoglobulin Adjunctive Therapy in Sepsis, with Special Emphasis on Severe Invasive Group A Streptococcal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Sepsis and polyspecific intravenous immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Adverse effects of intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Intravenous immunoglobulin for suspected or subsequently proven infection in neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

The microbiology and outcome of sepsis in Victoria, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

Predictive ability of meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001090

10.1002/14651858.CD001090

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference